3.48
-0.34(-8.90%)
Currency In USD
| Previous Close | 3.82 |
| Open | 3.66 |
| Day High | 3.95 |
| Day Low | 3.4 |
| 52-Week High | 5.14 |
| 52-Week Low | 0.64 |
| Volume | 121,889 |
| Average Volume | 2.11M |
| Market Cap | 15.87M |
| PE | -2.72 |
| EPS | -1.28 |
| Moving Average 50 Days | 2.93 |
| Moving Average 200 Days | 1.99 |
| Change | -0.34 |
If you invested $1000 in Lixte Biotechnology Holdings, Inc. (LIXT) 10 years ago, it would be worth $362.5 as of August 20, 2025 at a share price of $3.48. Whereas If you bought $1000 worth of Lixte Biotechnology Holdings, Inc. (LIXT) shares 5 years ago, it would be worth $49.15 as of August 20, 2025 at a share price of $3.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100
GlobeNewswire Inc.
10 hours ago
LIXTE Biotechnology’s LB-100 Featured in Nature Reviews Cancer Editorial: A Game-Changer in Cancer Therapy Resistance LIXTE’s Netherlands Cancer Institute research group published preclinical data, in Cancer Discovery, showing that LB-100 induce
LIXTE Biotechnology Holdings Provides Corporate Update
GlobeNewswire Inc.
Aug 18, 2025 12:00 PM GMT
-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- -Reports on New Findings Published in Scie
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
GlobeNewswire Inc.
Aug 15, 2025 1:06 AM GMT
Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24/7 Market News Issues Corrected Information on Previously issued Press Release with same title